Celsense

Celsense, Inc. is a privately held biotechnology company offering pre-clinical and clinical-grade imaging agents used to non-invasively detect, identify, quantify, and monitor cells and cellular activity. The company is based in Pittsburgh, Pennsylvania. It was founded in 2005 to commercialize imaging platforms developed at Carnegie Mellon University.
Celsense makes proprietary imaging agents for cell trafficking using magnetic resonance imaging (MRI) techniques. The company's products are used primarily to understand regenerative medicine, immunotherapy, inflammation, and immune system response. There are over 100 peer reviewed articles in the academic literature describing cell trafficking in vivo using Celsense products. The first clinical trial involving the use of Cell Sense CS-1000 was completed in 2014. Additional clinical trials are pending in the US and Canada.
Corporate structure.
Current members of the board of directors of Celsense are: Charles F. O’Hanlon, III, Thomas Petzinger, Jr., Abby Lembersky, L. Gerald Tarantino, and Gregory T. Hebrank.